Mayne Pharma signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise E4/DRSP in the United States.
Mayne Pharma CEO, Mr Scott Richards says the drug is expected to transform Mayne Pharma and accelerate the on-going pivot of the company into attractive specialty therapeutic segments in the United States like Women’s Health.
Shares in Mayne Pharma (ASX:MYX) are trading 2.59 per cent lower at $0.57.